Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) just unveiled an announcement.
JCR Pharmaceuticals Co., Ltd. announced the distribution of retained earnings as dividends, with a term-end dividend of 10.00 yen per share for the fiscal year ending March 31, 2025, matching the previous year’s dividend. This decision aligns with JCR’s policy of consistent profit distribution while maintaining reserves for new drug development and financial stability.
The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceuticals company focused on expanding possibilities for people with rare and genetic diseases. With a 50-year legacy in Japan, the company is expanding its global presence in the US, Europe, and Latin America. JCR applies scientific expertise and unique technologies to develop next-generation therapies, with approved products in Japan for conditions like growth disorder, MPS II, Fabry disease, and more. The company is also developing investigational products for rare diseases worldwide.
Average Trading Volume: 652,898
Technical Sentiment Signal: Sell
Current Market Cap: Yen58.29B
See more insights into 4552 stock on TipRanks’ Stock Analysis page.
Trending Articles:
- Daniel Ives Lifts Palantir (PLTR) to New Street-High Price Target, Stock Hits a Fresh 52-Week High
- “Boeing Has Backed Itself Into a Corner,” Says Union, Boeing Stock (NYSE:BA) Gains Anyway
- “You Received a Refund Within 24 Hours”: Elon Musk Claps Back on Sam Altman’s Refund Request, Tesla Stock (NASDAQ:TSLA) Surges